Table 2.

The Frequency of Anorexia and Related Adverse Events in Patients with Renal Cell Carcinoma Treated with VEGF/VEGFR TKIs

TKI	Phase	Arm	n	Anorexiaa	Weight Loss	Nausea	Vomiting	Diarrhea	Constipation	Stomatitis	Fatigue, Astheniab	Dysgeusia	Ref.
Sunitinib	3	TKI	535	25	NA	38	21	52	NA	28	66	33	Motzer et al41
		Control	547	14	NA	20	11	27	NA	4	50	6
Sunitinib	3	TKI	375	44	12	52	31	61	12	30	74	46	Motzer et al42
		Control	360	39	14	35	12	15	4	4	71	15
Sorafenib	3	TKI	451	16	10	23	16	43	15	NA	37	NA	Escudier et al45
		Control	451	13	6	19	12	13	11	NA	28	NA
Pazopanib	3	TKI	554	37	15	45	28	63	17	14	64	26	Motzer et al48
		Control	548	37	6	46	27	57	24	27	73	36
Axitinib	3	TKI	189	29	37	20	NA	50	NA	NA	54	NA	Hutson et al49
		Control	96	19	24	15	NA	40	NA	NA	42	NA
Cabozantinib	3	TKI	331	46	31	50	32	74	25	22	75	24	Choueiri et al53
		Control	322	34	12	28	14	27	19	24	62	9
Lenvatinib	2	TKI	52	58	48	62	39	72	37	25	50	NA	Motzer et al58
		Control	50	18	8	16	10	34	18	42	38	NA

Notes: ^aIncludes decreased appetite. ^bFatigue and asthenia are shown as a combined frequency. Adverse events are all shown as percentages.

Abbreviations: n, number of cases; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.